2024
American Association of Cancer Research Annual Meeting (AACR 2024) will be held
from April 5-10, 2024, in San Diego, United States. As the focal point of
the cancer research community globally, countless latest scientific and medical
studies in tumor field are first published here every year. In AACR 2024, one
study of drug candidate GT0486 and two pre-clinical studies (including an
anti-PD-1/ALK-1 bispecific antibody Nivo813 and a molecular glue GT19870) from
Kintor Pharma are selected. It demonstrates high research and development value
of drug and pre-clinical studies, also signifies that the company’s innovative
capabilities and potential for drug development have been internationally
recognized. The abstracts are available on AACR’s official website.Abstracts：GT0486（mTORC1/2）Title: GT0486, a novel mTORC1/2 dual inhibitor, exhibits synergistic antitumor efficacy in combination with BTK inhibitorsSession Category: Clinical ResearchSession Title: Targetin
………………………………
